Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06555458
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
The Effect of Sedation on Rebound Pain in Knee Arthroplasty
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of Sedation on Rebound Pain in Knee Arthrplasty Performed Under Spinal Anesthesia
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dexmedetomidine is often used for sedation procedures It has also been shown to have a pain-protective effect Researchers predicted that using dexmedetomidine for sedation in total knee arthroplasties performed under spinal anesthesia would reduce the frequency of rebound pain and pain scores
Detailed Description:
Randomization will take place before the patient enters the operating room After spinal anesthesia is applied 04 mcgkg sedadomide loading will be done for 10 minutes in the sedation group and then 04 mcgkgh sedadomide infusion will continue until the end of the surgery Patients selected for the control group will be given the same amounts of saline At the end of the surgical procedure saline and sedadomide infusions will be stopped All patients will undergo an adductor canal block under USG guidance in the recovery room 50 mg of buvacin will be given to the block area Patients will be fitted with a patient control analgesia device which only provides bolus application and provides 20 mg of madol in each bolus Postoperatively sudden onset severe withdrawal pain outside the normal course of pain starting within 48 hours will be followed and Vas-bromage monitoring will be done at 0 1 2 4 8 12 24 36 48 hours
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None